12:00 AM
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

2-hydroxypropyl-b-cyclodextrin: Phase I started

NIH said its National Center for Advancing Translational Sciences (NCATS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) began an open-label, dose-escalation, U.S. Phase I trial to evaluate 100,...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >